A shift in federal policy could bring psychedelics into mainstream medicine, as the Trump administration examines their therapeutic potential under pressure from the growing Make America Healthy Again movement. The Food and Drug Administration recently hosted a public hearing where more than 200 participants advocated for further research into substances long dismissed as fringe. With increased investment and scientific interest, the debate over legalization and medical applications is gaining momentum. The hearing marks a turning point in how psychedelics are viewed, potentially reshaping treatment approaches for mental health conditions.
The Trump administration, under the influence of the Make America Healthy Again (MAHA) movement, is exploring the potential use of psychedelic substances in medicine — once a fringe topic that is now being heavily researched and invested in. The Food and Drug Administration (FDA) held a public hearing in September in which over 200 people requested...
